Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 386

1.

Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.

Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, Rouzier R, Faure C, Paillocher N, Chauvet MP, Houvenaeghel G, Gutowski M, De Blay P, Verhaeghe JL, Barranger E, Lefebvre C, Ngo C, Ferron G, Palpacuer C, Campion L.

Breast Cancer Res Treat. 2018 Oct 20. doi: 10.1007/s10549-018-5004-7. [Epub ahead of print]

PMID:
30343457
2.

Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact.

Houvenaeghel G, de Nonneville A, Cohen M, Classe JM, Reyal F, Mazouni C, Chopin N, Martinez A, Daraï E, Coutant C, Colombo PE, Gimbergues P, Chauvet MP, Azuar AS, Rouzier R, de Lara CT, Muracciole X, Agostini A, Gonçalves A, Lambaudie E.

Breast Cancer Res Treat. 2018 Sep 20. doi: 10.1007/s10549-018-4944-2. [Epub ahead of print]

PMID:
30238274
3.

Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study.

Cariou A, Rouzier R, Baffert S, Soilly AL, Hequet D.

PLoS One. 2018 Aug 23;13(8):e0202385. doi: 10.1371/journal.pone.0202385. eCollection 2018.

4.

Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression.

Romero P, Benhamo V, Deniziaut G, Fuhrmann L, Berger F, Manié E, Bhalshankar J, Vacher S, Laurent C, Marangoni E, Gruel N, MacGrogan G, Rouzier R, Delattre O, Popova T, Reyal F, Stern MH, Stoppa-Lyonnet D, Marchiò C, Bièche I, Vincent-Salomon A.

Am J Pathol. 2018 Oct;188(10):2378-2391. doi: 10.1016/j.ajpath.2018.06.021. Epub 2018 Aug 1.

PMID:
30075151
5.

Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study.

Arfi A, Baffert S, Soilly AL, Huchon C, Reyal F, Asselain B, Neffati S, Rouzier R, Héquet D.

BMJ Open. 2018 May 18;8(5):e020276. doi: 10.1136/bmjopen-2017-020276.

6.

Adherence to Guidelines During Follow-up of Endometrial Cancer: Analysis of French Health Insurance Database.

Phelippeau J, Rouzier R, Koskas M.

Anticancer Res. 2018 May;38(5):2977-2982.

PMID:
29715127
7.

Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.

Basse C, Morel C, Alt M, Sablin MP, Franck C, Pierron G, Callens C, Melaabi S, Masliah-Planchon J, Bataillon G, Gardrat S, Lavigne M, Bonsang B, Vaflard P, Pons Tostivint E, Dubot C, Loirat D, Marous M, Geiss R, Clément N, Schleiermacher G, Kamoun C, Girard E, Ardin M, Benoist C, Bernard V, Mariani O, Rouzier R, Tresca P, Servois V, Vincent-Salomon A, Bieche I, Le Tourneau C, Kamal M.

ESMO Open. 2018 Apr 6;3(3):e000339. doi: 10.1136/esmoopen-2018-000339. eCollection 2018.

8.

The role of neoadjuvant chemotherapy in ovarian cancer.

Elies A, Rivière S, Pouget N, Becette V, Dubot C, Donnadieu A, Rouzier R, Bonneau C.

Expert Rev Anticancer Ther. 2018 Jun;18(6):555-566. doi: 10.1080/14737140.2018.1458614. Epub 2018 Apr 10.

PMID:
29633903
9.

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.

Ploquin A, Pistilli B, Tresch E, Frenel JS, Lerebours F, Lesur A, Loustalot C, Bachelot T, Provansal M, Ferrero JM, Coussy F, Debled M, Kerbrat P, Vinceneux A, Allouache D, Morvan F, Dalenc F, Guiu S, Rouzier R, Vanlemmens L.

Eur J Cancer. 2018 May;95:30-37. doi: 10.1016/j.ejca.2018.02.030. Epub 2018 Apr 3.

PMID:
29625257
10.

High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.

Bataillon G, Fuhrmann L, Girard E, Menet E, Laé M, Capovilla M, Treilleux I, Arnould L, Penault-Llorca F, Rouzier R, Marchiò C, Bieche I, Vincent-Salomon A.

Histopathology. 2018 Aug;73(2):273-283. doi: 10.1111/his.13514. Epub 2018 May 7.

PMID:
29537649
11.

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.

Hamy AS, Belin L, Bonsang-Kitzis H, Paquet C, Pierga JY, Lerebours F, Cottu P, Rouzier R, Savignoni A, Lae M, Reyal F.

Br J Cancer. 2018 Mar 20;118(6):e14. doi: 10.1038/bjc.2018.4. Epub 2018 Feb 20.

12.

[Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].

Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Chabbert-Buffet N, Daraï E, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, de la Motte Rouge T, Ferron G, Devouassoux-Shisheboran M, Kurtz JE, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, Ray-Coquard I.

Bull Cancer. 2018 Mar;105(3):299-314. doi: 10.1016/j.bulcan.2017.10.032. French.

PMID:
29397916
13.

Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.

Hamy AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga JY, Vincent-Salomon A, Coussy F, Becette V, Bonsang-Kitzis H, Rouzier R, Feron JG, Benchimol G, Laé M, Reyal F.

Breast Cancer Res Treat. 2018 Jun;169(2):295-304. doi: 10.1007/s10549-017-4610-0. Epub 2018 Jan 27.

PMID:
29374852
14.

Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR.

Generali D, Corona SP, Pusztai L, Rouzier R, Allevi G, Aguggini S, Milani M, Strina C, Frati A.

J Cancer Res Clin Oncol. 2018 Mar;144(3):601-606. doi: 10.1007/s00432-017-2574-4. Epub 2018 Jan 17.

PMID:
29344722
15.

A multidisciplinary approach to oncology trials: Study conduct of the ANTHALYA trial.

Ghazi Y, Laurent C, Dupin J, Pau D, Balouet S, Rocha Y, Joly F, Rouzier R, Menguy V.

Contemp Clin Trials. 2018 Feb;65:151-156. doi: 10.1016/j.cct.2017.12.012. Epub 2017 Dec 26.

PMID:
29287669
16.

Value of Diaphragmatic Surgery During Interval Debulking Surgery.

Pelissier A, Franke O, Darai E, Houvenaeghel G, Chereau E, Rouzier R.

Anticancer Res. 2018 Jan;38(1):411-416.

PMID:
29277802
17.

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.

Leung TF, Liu AP, Lim FS, Thollot F, Oh HML, Lee BW, Rombo L, Tan NC, Rouzier R, De Simoni S, Suryakiran P, Hezareh M, Thomas F, Folschweiller N, Struyf F.

Vaccine. 2018 Jan 2;36(1):98-106. doi: 10.1016/j.vaccine.2017.11.034. Epub 2017 Nov 23.

18.

[Mammary duct papilloma: How I do… a microdochectomy wire guided].

Chevrot A, Pelissier A, Rouzier R.

Gynecol Obstet Fertil Senol. 2017 Nov;45(11):632-633. doi: 10.1016/j.gofs.2017.09.003. Epub 2017 Oct 27. French. No abstract available.

PMID:
29111292
19.

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.

Hequet D, Callens C, Gentien D, Albaud B, Mouret-Reynier MA, Dubot C, Cottu P, Huchon C, Zilberman S, Berseneff H, Foa C, Salmon R, Roulot A, Lerebours F, Salomon A, Ghali N, Morel P, Li Q, Cayre A, Guinebretière JM, Hornberger J, Penault-Llorca F, Rouzier R.

PLoS One. 2017 Oct 18;12(10):e0185753. doi: 10.1371/journal.pone.0185753. eCollection 2017.

20.

Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.

Sesay S, Brzostek J, Meyer I, Donazzolo Y, Leroux-Roels G, Rouzier R, Astruc B, Szymanski H, Toursarkissian N, Vandermeulen C, Kowalska E, Van Damme P, Salamand C, Pepin S.

Hum Vaccin Immunother. 2018 Mar 4;14(3):596-608. doi: 10.1080/21645515.2017.1384106. Epub 2017 Nov 27.

21.

Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy.

Saule C, Mouret-Fourme E, Briaux A, Becette V, Rouzier R, Houdayer C, Stoppa-Lyonnet D.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx159.

PMID:
28954295
22.

Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.

Latreille-Barbier M, Rouzier R, Astruc B, Lavis N, Donazzolo Y.

Hum Vaccin Immunother. 2017 Nov 2;13(11):2674-2677. doi: 10.1080/21645515.2017.1363944. Epub 2017 Sep 22.

23.

Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.

Hamy AS, Pierga JY, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C, Vincent-Salomon A, Cottu P, Lerebours F, Rouzier R, Lae M, Reyal F.

Ann Oncol. 2017 Sep 1;28(9):2233-2240. doi: 10.1093/annonc/mdx309.

PMID:
28911063
24.

[Sentinel lymph node biopsy and neoadjuvant treatment in breast cancer].

Duraes M, Guillot E, Seror J, Pouget N, Rouzier R.

Bull Cancer. 2017 Oct;104(10):892-901. doi: 10.1016/j.bulcan.2017.08.003. Epub 2017 Sep 8. Review. French.

PMID:
28890124
25.

Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.

Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann L, Bonneau C, Deniziaut G, Melaabi S, Ng CCK, Marchiò C, Rouzier R, Bièche I, Vincent-Salomon A.

Mod Pathol. 2018 Jan;31(1):68-82. doi: 10.1038/modpathol.2017.107. Epub 2017 Sep 8.

PMID:
28884749
26.

[Genomic tests in early breast cancer management: Real-life experience].

Yazigi A, Callens C, Jaillot A, Lerebours F, Guinebretière JM, Rouzier R, Héquet D.

Bull Cancer. 2017 Oct;104(10):904-906. doi: 10.1016/j.bulcan.2017.07.002. Epub 2017 Aug 10. French. No abstract available.

PMID:
28803642
27.

[External multicentric validation of two scores predicting the risk of relapse in patients with borderline ovarian tumors: The nomogram of Bendifallah and the score of Ouldamer].

Pais P, Huchon C, Chevrot A, Cohen J, Fauconnier A, Rouzier R, Mimouni M.

Bull Cancer. 2017 Sep;104(9):721-726. doi: 10.1016/j.bulcan.2017.06.016. Epub 2017 Aug 1. French.

PMID:
28778341
28.

[Regression of vaccine coverage HPV: A French exception].

Héquet D, Rouzier R.

Gynecol Obstet Fertil Senol. 2017 Jul - Aug;45(7-8):443-444. doi: 10.1016/j.gofs.2017.06.009. Epub 2017 Jul 14. French. No abstract available.

PMID:
28716491
29.

Physician-to-physician communication in breast cancer care coordination.

Héquet D, Pouget N, Seror J, Huchon C, Robain M, Brédart A, Baffert S, Rouzier R.

Bull Cancer. 2017 Jul - Aug;104(7-8):690-693. doi: 10.1016/j.bulcan.2017.04.007. Epub 2017 Jun 8. No abstract available.

PMID:
28602384
30.

Diagnostic Performance of Ultrasound-Guided Fine-Needle Aspiration of Nonpalpable Breast Lesions in a Multidisciplinary Setting: The Institut Curie's Experience.

Farras Roca JA, Tardivon A, Thibault F, El Khoury C, Alran S, Fourchotte V, Marck V, Alépée B, Sigal B, de Rycke Y, Rouzier R, Klijanienko J.

Am J Clin Pathol. 2017 Jun 1;147(6):571-579. doi: 10.1093/ajcp/aqx009.

PMID:
28505308
31.

Evaluation and Selection of Quality Indicators for the Management of Endometrial Cancer.

Chenoz L, Phelippeau J, Barranger E, Bourdel N, Brun JL, Chereau E, Collinet P, Coutant C, Darai E, Deffieux X, Gautier T, Golfier F, Huchon C, Ouldamer L, Rouzier R, Koskas M.

Int J Gynecol Cancer. 2017 Jun;27(5):979-986. doi: 10.1097/IGC.0000000000000980.

PMID:
28498258
32.

Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).

Houvenaeghel G, Lambaudie E, Cohen M, Classe JM, Reyal F, Garbay JR, Giard S, Chopin N, Martinez A, Rouzier R, Daraï E, Colombo PE, Coutant C, Gimbergues P, Azuar P, Villet R, Tunon de Lara C, Barranger E, Sabiani L, Goncalves A.

Breast. 2017 Aug;34:24-33. doi: 10.1016/j.breast.2017.04.008. Epub 2017 May 3.

PMID:
28475932
33.

The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?

Aapro M, De Laurentiis M, Rea D, Bargallo Rocha JE, Elizalde R, Landherr L, Linderholm B, Mamounas E, Markopoulos C, Neven P, Petrovsky A, Rouzier R, Smit V, Svedman C, Schneider D, Thomssen C, Martin M.

Breast. 2017 Jun;33:191-199. doi: 10.1016/j.breast.2017.01.012. Epub 2017 Apr 22.

PMID:
28441617
34.

Preoperative clinical pathway of breast cancer patients: determinants of compliance with EUSOMA quality indicators.

Héquet D, Huchon C, Baffert S, Alran S, Reyal F, Nguyen T, Combes A, Trichot C, Alves K, Berseneff H, Rouzier R.

Br J Cancer. 2017 May 23;116(11):1394-1401. doi: 10.1038/bjc.2017.114. Epub 2017 Apr 25.

35.

European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer.

Oonk MHM, Planchamp F, Baldwin P, Bidzinski M, Brännström M, Landoni F, Mahner S, Mahantshetty U, Mirza M, Petersen C, Querleu D, Regauer S, Rob L, Rouzier R, Ulrikh E, van der Velden J, Vergote I, Woelber L, van der Zee AGJ.

Int J Gynecol Cancer. 2017 May;27(4):832-837. doi: 10.1097/IGC.0000000000000975.

PMID:
28441255
36.

Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: the MSKCC nomogram and the Tenon score. Results of the NOTEGS study.

Rouzier R, Uzan C, Rousseau A, Guillot E, Zilberman S, Meyer C, Estevez P, Dupre PF, Kere D, Doridot V, D'halluin G, Fritel X, Pouget N, Jankowski C, Mazouni C, Simon T, Coutant C.

Br J Cancer. 2017 Apr 25;116(9):1135-1140. doi: 10.1038/bjc.2017.47. Epub 2017 Mar 21.

37.

Determinants of geographic inequalities in HPV vaccination in the most populated region of France.

Héquet D, Rouzier R.

PLoS One. 2017 Mar 3;12(3):e0172906. doi: 10.1371/journal.pone.0172906. eCollection 2017.

38.

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.

Bonsang-Kitzis H, Mouttet-Boizat D, Guillot E, Feron JG, Fourchotte V, Alran S, Pierga JY, Cottu P, Lerebours F, Stevens D, Vincent-Salomon A, Sigal-Zafrani B, Campana F, Rouzier R, Reyal F.

PLoS One. 2017 Feb 27;12(2):e0169962. doi: 10.1371/journal.pone.0169962. eCollection 2017.

39.

[Androgen receptors in breast cancer: Expression, value and therapeutic prospects].

Héquet D, Mzoughi S, Rouzier R, Guccione E.

Bull Cancer. 2017 Apr;104(4):363-369. doi: 10.1016/j.bulcan.2017.01.005. Epub 2017 Feb 16. Review. French.

PMID:
28216075
40.

[Review of national and international guidelines for sentinel lymph node biopsy and complementary axillary dissection in breast cancer].

Vincent L, Margueritte F, Uzan J, Owen C, Seror J, Pouget N, Guillot E, Rouzier R.

Bull Cancer. 2017 Apr;104(4):356-362. doi: 10.1016/j.bulcan.2017.01.001. Epub 2017 Feb 15. Review. French.

PMID:
28214005
41.

Clinical validation of a model predicting the risk of preterm delivery.

Dabi Y, Nedellec S, Bonneau C, Trouchard B, Rouzier R, Benachi A.

PLoS One. 2017 Feb 9;12(2):e0171801. doi: 10.1371/journal.pone.0171801. eCollection 2017.

42.

Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.

de Nonneville A, Gonçalves A, Zemmour C, Classe JM, Cohen M, Lambaudie E, Reyal F, Scherer C, Muracciole X, Colombo PE, Giard S, Rouzier R, Villet R, Chopin N, Darai E, Garbay JR, Gimbergues P, Sabiani L, Coutant C, Sabatier R, Bertucci F, Boher JM, Houvenaeghel G.

Breast Cancer Res Treat. 2017 Apr;162(2):307-316. doi: 10.1007/s10549-017-4136-5. Epub 2017 Feb 2.

PMID:
28155054
43.

Colpoplasty by laparoscopic modified Davydov's procedure.

Seror J, Roulot A, Guillot E, Rouzier R.

Gynecol Oncol. 2017 Mar;144(3):647-648. doi: 10.1016/j.ygyno.2017.01.004. Epub 2017 Jan 9.

PMID:
28081882
44.

Denaturing fixatives are compatible with the NanoString nCounter® platform and the Prosigna® assay.

Rouzier R, Roulot A, Jeiranian AH, Ram N, Guinebretiere JM, Salomon AV, Gentien D.

N Biotechnol. 2017 May 25;36:37-41. doi: 10.1016/j.nbt.2017.01.001. Epub 2017 Jan 6.

PMID:
28069519
45.

Multidisciplinary management of advanced ovarian cancer for an optimal therapeutic strategy.

Heudel PE, Devouassoux-Shisheboran M, Taieb S, Genestie C, Selle F, Morice P, Rouzier R, Ray-Coquard I.

Eur J Gynaecol Oncol. 2017;38(2):175-180. Review.

PMID:
29953774
46.

[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]].

Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Llorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG).

Bull Cancer. 2016 Nov;103(11):951-952. doi: 10.1016/j.bulcan.2016.10.009. Epub 2016 Oct 28. French. No abstract available.

PMID:
28029350
47.

Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects.

Scherrer D, Rouzier R, Noel Barrett P, Steens JM, Gineste P, Murphy RL, Tazi J, Ehrlich HJ.

J Antimicrob Chemother. 2017 Mar 1;72(3):820-828. doi: 10.1093/jac/dkw458.

PMID:
27999038
48.

Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.

Rouzier R, Gouy S, Selle F, Lambaudie E, Floquet A, Fourchotte V, Pomel C, Colombo PE, Kalbacher E, Martin-Francoise S, Fauvet R, Follana P, Lesoin A, Lecuru F, Ghazi Y, Dupin J, Chereau E, Zohar S, Cottu P, Joly F.

Eur J Cancer. 2017 Jan;70:133-142. doi: 10.1016/j.ejca.2016.09.036. Epub 2016 Dec 1.

49.

Tumoral heterogeneity of breast cancer.

Roulot A, Héquet D, Guinebretière JM, Vincent-Salomon A, Lerebours F, Dubot C, Rouzier R.

Ann Biol Clin (Paris). 2016 Dec 1;74(6):653-660. Review.

PMID:
27848916
50.

Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.

Jankowski C, Guiu S, Cortet M, Charon-Barra C, Desmoulins I, Lorgis V, Arnould L, Fumoleau P, Coudert B, Rouzier R, Coutant C, Reyal F.

Breast Cancer Res Treat. 2017 Jan;161(1):73-81. doi: 10.1007/s10549-016-4040-4. Epub 2016 Nov 2.

PMID:
27807808

Supplemental Content

Loading ...
Support Center